Actuality: Typical clinical manifestations of growth and development of uterine myoma is often accompanied by an increasing menstrual
blood loss, and sometimes uterine bleeding, which some researchers consider “dysfunctional”, and mainly dependent “neuroendocrine
disorders”. Thus, intraoperative blood loss, can act as an aggravating factor during the perioperative period. Reduced
blood loss is an urgent problem in patients with uterine cancer, which is planned surgery.
Materials and Methods: Examined the results of surgical treatment of 114 patients with a diagnosis of giant uterine myoma. Research
conducted at the Department of Gynecology and intensive therapy Odessa Regional Hospital in 2014 - 2017. The average age
of patients with uterine myoma was 44,31 ± 5,35 yeasrs. Blood clotting system was investigated using low-frequency piezoelectric
thromboelastography.
Results: In the preoperative period in patients with giant uterine myomas was found activation of fibrinolysis, increasing of platelet
aggregation and hypercoagulability. Patients with uterine cancer had structural and chronometric activation of vascular-platelet
hemostasis with an increased generation of thrombin and the activation of the fibrinolytic activity of the blood
